

1 A COMBINATION AND METHOD PRESENTING AND UTILIZING DNA ANALYSIS
2 AND FOR DIAGNOSIS AND TREATMENT

3 CONTINUATION DATA

4
5 This invention is a continuation-in-part of Provisional Application 60/227,151 filed
6 August 22, 2000, Provisional Application 60/297,816 filed June 13, 2001, and Provisional
7 Application 60/263,486 filed January 23, 2001, and a provisional application of this name filed
8 on the same day as this application, which provisional applications are incorporated by reference.

9 SUMMARY OF INVENTION

10 After a patient or client has had all or critical DNA sequences determined, the inventors
11 propose a system of proposed treatment. The invention proposed to accomplish a determination
12 by a combination of machines and instruments. The invention proposes to compare a client's or
13 patient's genotypic expression reflected in the DNA sequences with databases of genotypic
14 expression associated with various diseases and afflictions. After such comparison, if or when
15 propensities to diseases or afflictions are determined, the invention proposes to investigate the
16 glutathione pathway functionality and redox imbalance to determine further treatment, and then to
17 administer treatment, particularly treatment by cystine, to restore proper glutathione levels. Other
18 treatments for other chemical cycle imbalance may be indicated as well.

19 For further clarification of a propensity based on a genotypic expression, DNA sequence
20 determination among relatives can be helpful. Samples could be taken immediately after death in
21 conjunction with funeral arrangements for the purposes of determining a propensity to disease and
22 risk factors of disease based on detected sequences synonymous or similar to known sequences or
23 for propensities and risk factors statistically apparent based on manifested symptoms in such

1 relatives. By taking a sample of a baby at birth, and taking a sample later in life, and comparing
2 those samples to parent DNA, a determination can be made if a critical DNA change occurred
3 during a person's life time or was inherited. Determination can be made of whether an
4 environmental factor may have or may be causing or aggravating genotypic potential.

5 The first step is to have DNA sequence analysis performed of DNA samples.

6 Description and presentation of data

7 Upon completion of DNA sequencing, the inventors propose to compile the information
8 into electronically readable profiles stored in a form accessible by a general purpose computer.

9 Those profiles would be electronically scanned for sequences of specific alleles. Those specific
10 sequences from the selected profile would be compared to data bases with known sequences of
11 alleles reflecting potential risks or actual alleles found with respect to specific diseases or afflictions.

12 The analysis would be delivered to the client electronically or in other electronic media form
13 such as CD-ROM or disk. A hard copy of key data would be prepared. The invention includes
14 placing data on a CD-ROM in a form compatible for interface with a variety of software.

15 Translation software to make the data compatible with outside programs would be included if need
16 on the electronic media delivered, or a hyperlink to where a patient, client or health care provider
17 could purchase such software would be included. A patient, on a personal computer, could view
18 key or selected data and print a hard copy of key DNA profiles.

19 From the analysis, where there were matching sequences to known sequences indicating a
20 propensity(ies) of disease or affliction, hyperlinks would be generated from a second data base
21 corresponding to the DNA genetic markers to enable a client to obtain further information. The
22 database can on a compact disk (CD), or alternatively, accessible by electronic means, usually

1 through the Internet. These hyperlinks could be generated for two purposes. The first is to
2 enable access to general information understandable by a layperson. The second is to enable
3 access by a more sophisticated client or his health care provider to either other data bases or
4 detailed literature.

5 Another feature of the electronic delivery system would be to have a security system so only
6 the client and the client's selected personal choices could access the sequence information
7 delivered. The proposed electronic delivery system would have a password system and software
8 either programmed on electronic media or separately communicated to a client so that access to
9 electronic media would only be by password. The method would alternatively contemplate
10 transmission of the password separately from such electronic media by a postcard or independent
11 secure electronic communication. A client could also direct transmission of data to his health care
12 provider, and a password could be provided to a health care provider to enable that person to have
13 unique access. **Application:**

14 While reference is directly made in this disclosure to use in humans and persons,
15 wherever such expression is used, it shall mean application to animals and in particular veterinary
16 science. The claims are not limited to human analysis or therapy.

17 A positive application of the power of analysis of such DNA sequences is a method of
18 analysis and consequent administration of appropriate drug therapy in specified situations. For
19 diseases such as Alzheimer's, cancer, AIDS, Amyotrophic lateralsclerosis [ALS], multiple sclerosis,
20 cystic fibrosis, pneumonia, asthma, bronchial hyperresponsiveness and atopy, chronic obstructive
21 pulmonary disease ("COPD") and many bacterial infections, they are either caused by, or reflect
22 an imbalance of redox and consequent glutathione depletion. That glutathione depletion is more

1 indicative of a particular problem pointing to a particular therapy as described in this invention
2 than diminished anti-oxidant capacity of the body as a result of disease. Similarly, the invention is
3 useful in connection with uncontrolled macrophages usually manifested by exaggerated
4 inflammatory response, such as septicemia and in mutomuscular diseases. Meningococcal
5 infections are enhanced by the therapy of propensity and treatment under this invention. Even if
6 not curative, restoration or amelioration of glutathione depletion is therapeutic. In the event of
7 trauma, often the stress of trauma complicates other bodily functions. Restoration of the
8 functionality of the glutathione cycle improves the efficacy of other therapy. Therapy to increase
9 anti-oxidant capacity is also ameliorative.

10 A different and useful of this invention is determination by evaluation of DNA sequences
11 of the therapeutic value of vaccination. Those with "weaknesses," for instance, in the GSM
12 (glutathione-S-transferase mu, also called "GST-mu" or "GSTM") genotypic expression, suggesting
13 a propensity to glutathione depletion and redox imbalance will be more susceptible to aggravated
14 symptoms and deleterious effects of diseases. If a vaccine exists for such a disease, a vaccine would
15 be more therapeutic for a person with such a propensity to glutathione depletion and redox
16 imbalance. An example is Group B meningococcus (Neisseria meningitis) where a patient with
17 propensities reflected in GSM genotypic expression to glutathione depletion and would find a
18 vaccine more therapeutic than a person without such a propensity. If there was a vaccine risk,
19 those hwo had a GSM defect would be more likely to take the vaccine risk, rather than face the
20 increased risk from less effective immune response to Group B meningococcus that results from a
21 GSM defect.

1 For military personnel faced with close living, or with vaccination for anthrax or other
2 biological warfare agents, DNA testing for GSM or CYP450 defects would be important to pre-
3 select personnel more prone to complications, who could be pre-administered cystine or other
4 glutathione pathway enhancing and detoxifying compound as later discussed.

5 Having rendered the sequence(s) of DNA alleles from a client or patient in electronically
6 readable form, such as by a Perkin-Elmer/PE Biosystems model ABI PRISM 377 DNA
7 Sequencer, U.S. Pat. 5,543,026, Hoff et al, August 6, 1996, and associated software sold with that
8 instrument in electronically readable form, the inventors could be electronically examining the
9 sequences stored for a biochemical defect suggestive of redox imbalance. That examination would
10 be done by comparing the sequences of a particular client with a data base of known sequences of
11 alleles reflecting potential risks or actual alleles found with respect to specific diseases or afflictions.

12
13 Previously, the direct attack of gene by gene, allele by allele comparison, a massive
14 investigation of DNA sequences has been impractical because of the limited speed of general
15 purpose computing machines, limited storage capacity, and insufficient knowledge of the complete
16 human DNA chain. The optimal means of investigation is to examine DNA sequences on
17 chromosomes known to evidence genotypic expression of concern, as opposed to examining the
18 entire DNA sequence in every instance. See, Fryer AA, Bianco A, et al, Am J. Respirator and
19 Critical Care Medicine May 2000, 161(5): 1437-42. Recent enhancements in the speed of
20 generally available computing machines, such as 1300Mhz, and terabyte storage render massive
21 analysis practical. The compilation of the human genome sequence enables practical comparison
22 and knowledge of DNA sequences suggesting propensity to various afflictions, examples of which

1 are cited in this invention, though the invention and method is not limited to the specific examples
2 cited.

3 As previously stated, the invention is a system of proposed treatment based on knowledge
4 of the DNA sequence, comparison with databases of genotypic expression associated with various
5 diseases and afflictions, and from there, when propensities are shown, investigation by examination
6 of the glutathione pathway functionality and redox imbalance to determine further treatment,
7 particularly treatment by cystine, to restore proper glutathione levels. For other genotypic
8 expressions, other treatments to restore proper function of the glutathione pathway and redox
9 potential are indicated, but in any event, knowledge of the DNA sequences and the determination
10 of glutathione pathway functionality and/or redox imbalance would be made according to the
11 methods in this invention. Nedechewa K, Andersen, T Erikstein B, Nesland et al, Institute for
12 Cancer Research, The Norwegian Radium Hospital, Dept. of Genetics, Home Staff Scientific
13 Interest Publications Links available on Internet.

14 The addition of yet another step, testing and measuring the anti-oxidant capacity of the
15 body is a further refinement of the invention as a diagnostic tool. Again, the entire population
16 could be tested for anti-oxidant capacity of the body, but such testing is not cost-effective. The
17 DNA sequence analysis, comparison with known sequences to determine genotypic expressions
18 and disease propensity, and testing for glutathione deficiency as indicated and for anti-oxidant
19 capacity, as indicated, enable sophisticated and earlier evaluation of patent and latent disease
20 conditions.

21 The examination of the presence of certain genes as indicating a propensity to disease such
22 as breast cancer is stated in the art. Based on the ability to determine DNA sequences, and the

1 compilation of human genome sequences, the invention contemplates the novel step of identifying
2 gene sequences to an individual, and then comparing the gene sequences with a database of known
3 DNA sequences, and thereupon determining a propensity to a certain disease or disease state by
4 storage and testing of DNA. The entire DNA need not necessarily be examined, for instance of an
5 ancestor, until a necessary testing state is indicated, and the invention contemplates storage pending
6 such need. Selection of key chromosomes and genetic sequences for deductive analysis of a
7 patient's propensity based on known gene sequences indicating propensity is contemplated. The
8 invention discusses later the development of such information and exemplary gene sequences to
9 analyze.

10 Moreover, the invention recognizes that GST and GSM- μ 1 defects are not the only
11 significant genotypic expressions. Other genotypic expressions may lead to other defects in
12 biochemistry and in particular biochemical cycles. This invention includes examination of other
13 gene sequences to determine genetic propensity to disease and the examination of redox potential
14 in applicable cycles, which will often and usually include the glutathione cycle. Upon such
15 examination of redox potential, administration of therapy should be given to not only balance
16 glutathione cycle malfunction, but also to ameliorate malfunction and redox imbalance in other
17 cycles.

18 The method includes the additional possibility of drawing and analyzing samples drawn
19 from grandparents, parents, siblings or other relatives to further clarify propensity. Such samples
20 could be taken immediately after death in conjunction with funeral arrangements for the purposes
21 of determining propensity and risk factors based on detected sequences synonymous or similar to
22 known sequences or statistically apparent based on manifested symptoms in such relatives. Such

determination of propensity in relatives of a particular client could be used to optimize selection of DNA sequences and alleles to study in a particular client.

Examination of critical DNA sequences of a patient's ancestors' prior to or contemporaneous to death while DNA is intact offers an opportunity to detect if genotypic DNA is inherited or is a result of an environmental influence or other mutation. Examination would first be made of corresponding genes which should be or could be present by inheritance, and then comparing gene sequences of a parent with a child to see if they properly coincide.

One of the most important databases of sequences to examine is a database of DNA sequences associated with glutathione S-transferase ("GST"). For example, by accessing a database having the sequences of glutathione S-transferase mu 1 ("GST μ 1") defects, and electronically scanning the client's electronically stored DNA sequence, we can determine if GST μ 1 defects exist. Those defects, if present, indicate a genotypic predilection to many disease states. Other examples include examination for GSTP1, GST1 referenced in Curran, Weinstein, Griffiths, Cancer Letter May 29 2000, 153(1-2): 113-20. Other literature references five related gene classes to GST referenced as classes alpha, mu, pi, sigma, and theta. Hayes, Pulford, Critical Review Biochemistry Molecular Biology 30(6): 445-600 (1995). The level of expression of GST is asserted to be a crucial factor in determining the sensitivity of cells to a broad spectrum of xenobiotic (potentially toxic) chemicals. Overexpression in certain cases can be as deleterious as underexpression in others. Another example of the importance is cytochrome P450 2E1 ("CYP2E1") a defect which is suggested to be associated to susceptibility to development of esophageal cancer. See, Tan W, Song N, Wang GQ, Liu A, Tang HJ et al, Cancer Epidemiology

1 Biomarkers Prev 2000 Jun, 9(6): 551-6. The cytochrome P450 DNA gene sequence will be
2 generally referred to as CYP450.

3 The manifestation of those disease states is reflected in imbalance in redox potential. The
4 method proposed in this invention enables potentially earlier detection of susceptibility to a
5 particular disease state, earlier detection of latent onset of a disease, and as will be described, more
6 accurate clinical therapy for a client manifesting symptoms of a disease.

7 In the situation of a GST μ 1 defect, and in actual observation of redox imbalance, a client
8 would be consulting a health care provider for a protocol to restore redox potential and enable
9 optimal administration of suitable supplements, ameliorative substances or drug therapy to
10 optimize the glutathione pathway. For instance in situations where treatment would normally
11 involve surgery of a manifestation of a disease, such as a tumor, or "watchful waiting" for
12 manifestation and then treatment, the administration of cystine to increase the competency of the
13 immune system prior to such manifestation and delay such manifestation results in reduced
14 medical costs and increase in quality of life as well as reduction of the stress of "watchful waiting."
15 The invention contemplates that the determination of the propensity to glutathione deficiency
16 would suggest more frequent testing and therapy to forestall glutathione therapy.


17 Several specific applications are as follows. For patients on a ventilator, the patient's DNA
18 sequences could be compared to databases of defects indicating a propensity to redox imbalances
19 in the glutathione pathway. In any event, for patients on a ventilator, determination would be
20 made if there are redox imbalances which are associated with the glutathione pathway. A redox
21 imbalance implies that peroxidative injury is occurring and the glutathione cycle is malfunctioning.

Measurement of antioxidant capacity or for purposes of a patient with a problem, incapacity, showing a redox imbalance will be discussed later.

The importance is that glutathione can protect hemoglobin and other critical blood cell proteins from peroxidative injury. Glutathione reductase links the pathway to the hexose monophosphate pathway through the reversible oxidation and reduction of NADP. Glutathione peroxidase effects the conversion OH^\cdot to water, thus reducing the likelihood of peroxidative denaturation of hemoglobin and other proteins.

Glutathione level test:

Determination of glutathione levels for plasma and/or red blood cells is the preferred test. Red blood cell glutathione measures oxidized and reduced glutathione in the red blood cells. The predominant form is the reduced form of glutathione. Plasma glutathione measures total glutathione plus all other thiols and thiol containing proteins present in plasma. If a separately performed assay of plasma glutathione is done by high performance liquid chromatography (HPLC), the amount determined by that test can be subtracted from plasma glutathione to yield total thiol. The test of glutathione is performed according to F. Tietze, 1968 Enzymic Method for the Quantitative Determination of Nanogram Amounts of Total and Oxidized Glutathione Analytical Biochemistry with an additional reference of F. Tietze, 2nd ed., Chemical Chemistry 1994, pp. 1779-1780. This Tietze method has been modified as follows:



1 where GSSG is glutathione, oxidized
2 GR is glutathione reductase
3 DTNB is a sulfhydryl reagent 5, 5'-dithiobis-(2-nitrobenzoic acid)
4 G-SH is glutathione, reduced
5 DTN⁺ is dithiobisnitrobenzoic acid
6 GS⁻ is a transition state between glutathione reduced and oxidized
7 The method of glutathione assay provides a sensitive method for total and oxidized
8 glutathione. The modification increases sensitivity for spectrophotometric analysis. The reagents
9 in use throughout this invention, including for this test, are either generally available for a chemical
10 supply house or available from Sigma Chemical Co., Inc. or a company associated with it, Aldrich
11 Chemical Company, of St. Louis, Missouri, incorporating DTNB, a sulfhydryl reagent 5, 5'-
12 dithiobis-(2-nitrobenzoic acid) in the first reaction which possesses a molar absorption at 412 mμ
13 then forms two moles of GSH per mole of reduced nucleotide utilized in the GSSG reduction in
14 reaction (2). The rate of chromophore development depends on the concentration of glutathione
15 in the reaction mixture detectable to 10 nanograms ml⁻¹. This provides a highly sensitive and
16 specific procedure for measuring glutathione. The normal level should be approximately 200-
17 400micromoles/liter for plasma and red blood cells. The test may be performed on an automated
18 clinical chemistry analyser (also called a random access analyzer) such as Roche Cobas Fara.
19 Samples are collected carefully to prevent contamination. Frozen plasma collected from ACD,
20 EDTA, and heparin may be used. The invention could test reduced glutathione but there is not
21 any efficacy over testing total glutathione. Upon determining a redox imbalance or suboptimal
22 glutathione cycle function, the next step in the preferred mode of treatment protocol would be

1 administering cystine, normally in the amount of be 140mg/70 Kg man twice per day. The cystine
2 feeds into the glutathione pathway and substantially reduces a stay on a ventilator with substantial
3 cost savings and therapeutic effect. A discussion of the therapeutic value of appropriate levels in
4 the glutathione pathway is discussed in Rahman I, MacNee W, Free Radical Biological Medicine
5 2000, May 1, 28(9): 1405-1420, and in particular as associated with inflammatory lung diseases.

6 Cystine will be used as a generic reference for a glutathione pathway enhancing and
7 detoxifying compound. Cystine is the preferred compound to be used as a glutathione pathway
8 enhancing and detoxifying compound. Such glutathione pathway enhancing and detoxifying
9 compounds include the following:

10 Cystine is (3,3'-dithiobis [2-aminopropanoic acid]). Cystine is readily reduced to
11 cysteine. Cystine is present in most mammalian hair and keratin.

12 Cysteine is 2-amino-3-mercapto propanoic acid. It is readily converted by oxio-reduction
13 to cystine. It is a constituent of glutathione and abundantly present in the metallothioneines.

14 Cystine in the body-useful form as L-cystine is available from Spectrum Chemical Mfg.
15 Corp. 14422 S. San Pedro St., Gardena, California 90248.

16 Cystine, cysteine, and N-Acetyl cysteine and pharmaceutically acceptable salts, including
17 the pharmaceutically active forms described in Kozhemyakin et al, published by WIPO as
18 WO 00/031120, PCT/RU99/00453, filed internationally on 19 Nov. 1999, "Hexapeptide with the
19 Stabilized Disulfide Bond and Derivatives Thereof Regulating Metabolism, Proliferation,
20 Differentiation and Apoptosis," will all collectively be referred to as cystine in this invention.
21 Included in the term cystine is also any therapeutically beneficial sulfur donating compound,
22

1 including ebselen, which interacts with the glutathione pathway. The invention contemplates in
2 the term cystine undenatured whey protein products designed to have enhanced cystine
3 concentration as well as protein products which contain cysteine and cystine. They can be in the
4 form of food products. Immunocal® whey protein diet supplement by Immunotek Research Ltd.
5 of Montreal Quebec is a useful product with cystine.

6 The addition of cystine, cysteine, N-acetyl cysteine, or the pharmaceutically acceptable
7 salt of those substances yields another effect in this invention not facially evident from the
8 independent properties of the basic components of the invention. Administration of a glutathione
9 pathway enhancing and detoxifying compound, preferably cystine, which has the best and most
10 rapid upload into the glutathione pathway and better storage capability by the body, or N-acetyl
11 cysteine, enhances the immune system competency of the patient.

12 All of these cystine and cystine-like compounds function as a glutathione pathway
13 enhancing and detoxifying compound. They have the additional benefit of ameliorating the
14 negative renal, hepatic and gastric effects of COX-2 inhibitors and HMG-CoA inhibitors, both as
15 a combination and individually. The enhancement of the glutathione level and pathway has a
16 second important and unexpected effect. The avoidance of a glutathione deficiency steers the
17 patient to have a higher Th-1 response to Th-2 response ratio than the patient would have with
18 any glutathione deficiency

19 Anti-oxidant capacity is best measured by measuring the capacity of human plasma. The
20 recommended procedure is to measure the antioxidant capacity of plasma saliva and
21 bronchoalveolar lavage fluid based on the absorbance of the ABTS^{•-}. On exposure to hydrogen
22 peroxide, metmyoglobin and methemoglobin are activated to ferryl states in which the iron is one

1 oxidizing equivalent above the original level and one oxidizing equivalent is on the surface of the
2 protein. With reducing agents, these species are reduced back to metmyoglobin or
3 methemoglobin.

4 Anti-Oxidant capacity test:

5 The procedure has been applied to physiological antioxidant compounds and radical
6 scavenging drugs. The basic principles of the procedure are as follows. An antioxidant ranking has
7 been established based on their reactivity to a 1.0 mM/L TROLOX standard. The peroxidase
8 activity of metmyoglobin combined with its interaction forms a radical cation intermediate with a
9 phenothroline compound. The method derives from the observation that when 2,2'-azinobis-3-
10 ethylbenzo thiazoline-6-sulphonic acid (ABTS) is incubated with peroxidase and hydrogen
11 peroxide, the relatively long-lived radical cation, ABTS^{•+} is formed. A large number of free
12 radicals such as hydroxyl, peroxy, alkoxy and inorganic radicals also react rapidly with ABTS to
13 form this species. When the peroxidase is metmyoglobin, the formation of the ABTS^{•+} radical
14 cation in interaction with ferrylmyoglobin has spectral absorption maxima at 650 nm, 734 nm and
15 820 nm, beyond the region of the heme proteins. In the presence of antioxidant reductants and
16 hydrogen donors in plasma, the absorbance of this radical cation is quenched to an extent related
17 to the antioxidant capacity.

18 The major antioxidant defenses in plasma include ascorbate, protein thiols, bilirubin, urate
19 and α -tocopherol. The "chain-breaking or "radical scavenging" agents against oxidative stress act in
20 the above sequence of increasing or decreasing effectiveness against free radicals generated in the
21 plasma aqueous phase. Plasma also contains the "preventive" antioxidants, ceruloplasmin and
22 transferrin, the iron-scavenging proteins whose contribution to the overall antioxidant capacity is to

1 prevent iron availability. Applying this method, the total plasma antioxidant status of an individual
2 can be determined supporting the need for antioxidant supplementation as well as the monitoring
3 of blood levels ranging from pregnancy (preterm infants), adults with COPD and asthma.

4 Speciman collection and handling:

5 Universal Precautions Apply.

6 Fresh plasma samples (EDTA or Citrated) should be used.)

7 See skin puncture collection of plasma, in Standard Laboratory Procedure Manual

8 See venipuncture collection of plasma in Standard Laboratory Procedure Manual

9 Blood should be collected aseptically and separated by standard laboratory techniques.

10 Contamination or introduced particulate matter can interfere with absorbance leading to
11 erroneous results. Critically, it is the plasma anti-oxidant capacity being measured, not that
12 of the white or red blood cells. That too can be measured, but is less reliable in certain
13 circumstances.

14 Storage of sample:

15 Samples can be stored at -20 degrees C for up to three (3) months. Avoid repeated
16 freeze-thaw cycles. Do not store samples in a self-defrosting freezer. If samples are not
17 assayed within twenty four (24) hours of collection, the samples must be stored at -20
18 degrees.

19 Materials and Equipment:

20 Test Instruments or equivalent to be utilized:

21 Manual: Variable wavelength Spectrophotometer

22 Automated: Roche Cobas Fara

1 **Materials:**

- 2 1. Phosphate buffered saline ("PBS"), pH 7.4
- 3 2. Myoglobin (Molecular Weight ["MW"]18,800 or 17,600), 400 μ M in PBS
- 4 3. Potassium Ferricyanide $K_3Fe(CN)_6$, MW 329.2, 740 μ M in PBS
- 5 a. Prepare the double strength of the solution 2 and 3
- 6 Mix well and maintain at ambient temperature for 15 minutes.
- 7 b. Dialyse against 400 mL PBS at +4°C; then re-dialyse with fresh buffer; change of
- 8 buffer after 2 hour interval and last dialysis for 20-30 minutes.
- 9 c. Read the absorbance at 490, 560, 580 and 734 nm and calculate the metmyoglobin
- 10 (MetMb) concentration using Whitburn's equation:
- 11 d. This solution is the stock solution and can be stored at -20degrees C for up to 4
- 12 weeks.
- 13 e. Working solution: Dilute with appropriate volume of PBS to give a final MetMb
- 14 concentration of 70 μ mole/L—stable at +4 degrees C for 1 week.
- 15 6. TROLOX® MW 250.29 [registered trademark of Hoffman LaRoche]: 97% fine white
- 16 powder manufactured by Aldrich Chemical associated with Sigma Chemical Co. of St.
- 17 Louis, Missouri.
- 18 a. Do not use yellow lumps, use white fine powder.
- 19 b. Stock solution: 2.5 mM in PBS, solution to be sonicated at high speed, store at -
- 20 20degrees C for up to 4 weeks
- 21 c. Working solution: 1:10 v/v with PBS, 0.25 mMole/L, stable 1 week at +4 degreesC

- 1 d. Standard curve: 2.5 nanomole to 12.5 nanomole
- 2 5. ABTS-2,2'-AZINOBIS (3-ETHYLBENZOTHAZOLINE-6-SULPHONIC ACID)
- 3 MW 548.7
- 4 a. Prepare FRESH—stable at ambient temperature for 24 hours, protect from light
- 5 b. Stock Solution: Prepare 5MM (5m Mole/L) solution in PBS
- 6 c. Working Solution: 1:10 dilution with PBS. (0.5 m Mole /L, stable at ambient
- 7 temperature for 24 hours, protect from light).
- 8 4. H_2O_2 (30% w/w), MW -34.01, 9.8M
- 9 a. Prepare fresh.
- 10 b. Calculate the concentration of 30% solution by taking absorbance at 240nm
- 11 c. Stock Solution 0.098M solution in PBS
- 12 d. Working Solution: 1:11 dilution with PBS (450 $\mu\text{mole /L}$)
- 13 Procedure:
- 14 1. To 1mL polystyrene square cuvette-1cm path length-
- 15 597 μL of PBS, pH 7.4
- 16 300 μL of ABTS solution
- 17 Desired volume of standards and unknown, and adjust the final volume with PBS:
- 18 36 μL of MetMb solution (70 $\mu\text{mole/L}$)
- 19 167 μL of H_2O_2 working solution.
- 20 1000 μL final volume

2. Use 10 μL to 50 μL : 2.5 n moles to 12.5 n moles to prepare a TROLOX standard curve.
3. 5-10 μL of plasma (on ice) (Heparinized). Mix well and invert by holding with parafilm and maintain for 12 minutes at ambient temperature and read immediately at 734 nm.

Results:

1. Plot a standard curve n moles /L TROLOX on x-axis; Absorbance reading at 734 nm on Y axis
2. Determine the TROLOX equivalent antioxidant capacity ("TEAC") in Mm) by using linear regression analysis compared to known absorbance of TROLOX.

The normal range will be 1.2-1.6milliMoles /liter. Patients exhibiting anti-oxidant capacities below 1.2 milliMoles/L demonstrate oxidative stress reflecting an imbalance in the redox system with a concomitant depletion of plasma glutathione. However, red blood cell and white blood cell glutathione may exceed the normal range as a result of the body's protective mechanisms. Administration of cystine to restore plasma glutathione levels is the efficacious and expeditious treatment.

Thus, propensity of glutathione imbalance by examination of a patient's DNA sequences, and a result indicating such propensity would suggest early intervention and aggressive investigation into redox imbalance and the state of the glutathione pathway.

For pregnant women, DNA sequencing would be performed and DNA sequences compared to a data base of sequences indicating a predisposition to preeclampsia. After comparing the DNA sequences to known defect sequences per the steps described, testing would

1 be undertaken to determine if there are redox imbalances, including those associated with the
2 glutathione pathway.

3 After such testing for propensity to preeclampsia, if the glutathione level was sub-optimal,
4 the next step in a protocol of treatment would be administering cystine or other appropriate drug
5 therapy. The cystine feeds into the glutathione pathway. Such treatment restores the health of the
6 mother more rapidly, and such treatment, after determining redox imbalances in the baby,
7 substantially reduces the time a baby delivered by a mother exhibiting symptoms or preeclampsia
8 would remain in a neonatal intensive care unit.

9 Recently a patent issued for "Intravenous magnesium gluconate for treatment of conditions
10 caused by excessive oxidative stress due to free radical distribution", William B. Weglicki, U.S.
11 Pat. 6,100,297, August 8, 2000. The abstract refers to the intravenous use of magnesium gluconate
12 to substantially block free radical surge in the treatment of ischemia/reperfusion (I/R) injury due to
13 oxidative stress.

14 The difference in this invention is that this invention proposes to first determine the genetic
15 propensity to glutathione imbalance, which is associated with free radical surge in the treatment of
16 ischemia/reperfusion injury due to oxidative stress. See, Mak et al, Circulation Research 70(6),
17 June 1991, pp. 1099-1103. By testing for glutathione level, and by determining the anti-oxidant
18 capacity of the patient, the necessity and acuity of condition for determination of use of the
19 Weglicki invention can be made.

20 The inventors also propose combination in sequence of devices associated with one or
21 more general purpose computers that have means for performing the above steps. The invention
22 contemplates a combination of a DNA sequence analyzer, and automated clinical chemistry

1 analyzer or random access biochemical analyzer such as the Roche Cobas Fara and a general
2 purpose computing machine having either a database of known genetic sequences and associated
3 propensities, and/or an additional data base of redox potentials and glutathione levels associated
4 with one or more particular diseases.

5 Potentially continuous sampling to automate and provide feedback to optimize therapy with
6 respect to detected redox imbalances and/or suboptimal glutathione levels is also contemplated
7 using the combination (without the DNA sequencer, which may or may not have been previously
8 done once a disease is manifested) in the prior paragraph. Upon restoration of proper glutathione
9 level, the therapy for biochemical balance could be automatically discontinued.

10 The foregoing contemplates a deductive method of treatment based on DNA sequences,
11 genetic propensities and determination of redox imbalance and glutathione level.

12 The invention also claims an inductive use of the invention. By analyzing redox imbalance,
13 and glutathione level in combination with actual disease manifestations, and then obtaining DNA
14 sequences of patients with such characteristics, existing databases can be enhanced, or new
15 databases developed. With the ability to actually review the entire human genome sequence,
16 statistically significant correlations by standard statistical methods, especially using statistical software
17 packages such as those available from SASS (Reg. Mark) can be used to associate DNA sequences
18 with redox imbalance and glutathione level as to certain disease manifestations. Such database can
19 then be utilized as the database of genotypic expression to compare with an unknown patient to
20 determine that patient's propensity to particular disease. A corollary of such a database is the ability
21 to associate redox imbalance and glutathione level in certain disease manifestations with severity or
22 advancement of disease.

1 Returning to the ventilator example, such a database would enable a patient on a ventilator
2 who had certain genotypic propensities to be evaluated, based on redox potential and glutathione
3 level for acuity of the situation. As a further part of that combination, an instrument for determining
4 redox imbalances in a patient could be integrated with the combination in the prior paragraph to
5 enhance and statistically adjust or build a data base to determine propensity based on actual redox
6 imbalances, and the reappearance of glutathione deficiency associated with gene sequences, and the
7 database could be examined for other statistically significant sequence coincidences.

8 For the preeclampsia example given, development of a database of known DNA sequences
9 so determination can be made of propensity to preeclampsia enables a health care provider to test
10 for redox imbalance and glutathione deficiency and make early determination of adverse bodily
11 state and acuity of any adverse condition.

12 Enhancement of a database would be done by having an instrument analyze DNA
13 sequences, and software associated with such instrumentation that then compiles the information
14 into electronically readable form. The novel combination would be to combine the electronically
15 readable information with software installed on the same or a linked general purpose computer
16 which software would perform an automated comparison with a data base of known sequences
17 indicating propensity to a particular redox imbalance and substitute in further information to alter
18 the database, which as the data base grows, artificially enhances the intelligence of the database for
19 diagnostic purposes.

20 In a sense, two related databases are developed. The first is a database for gene sequences
21 on certain chromosomes for indicating propensity, and enabling selection of critical DNA
22 sequences to examine, and the second database is, given a propensity and a certain redox

1 potential, glutathione level, and alternatively or additionally, determination of the anti-oxidant
2 capacity, what is the state of the manifestation, if any, of the indicated propensity. The anti-
3 oxidant capacity can be a predictive tool for likelihood of manifestation or stage of disease
4 illustrating the presence of disease symptoms, but glutathione is equally and more precisely
5 determinative.

6 Better yet is to have additional fields in the second database with objective patient data
7 such as blood pressure, temperature, blood analysis data, cholesterol, blood cell counts, cytokine
8 levels, and additional fields with less objective/more subjective data that can be electronically
9 manipulated such as Karnofsky performance criterion, or WHO recommendations for grading of
10 acute and subacute toxicity. Outcome data can be based on WHO recommendations for grading
11 of acute and subacute toxicity, including days/time to change as a result of therapy in a patient.
12 Many of these objective criteria can be seen in Provisional application 60/297,816 filed June 13,
13 2001, and Provisional Application Application 60/263,486 filed January 23, 2001 both entitled
14 "Adjuvant Immune Therapy in the Treatment of Solid Tumors through Modulation of Signaling
15 Pathways following Engagement of Humoral and Cell Mediate Responses." The data base can be
16 used to evaluate treatment methodologies given objective criterion, and as more patients are
17 entered in the data base, even if not accompanied by al the same fields of data, the data base can
18 be evaluated correlation between selected data and certain treatment methodologies if patient data
19 is not provided. As the database develops, missing data which is statistically determined to be
20 irrelevant to the selection of treatment would be output and so indicate irrelevancy. For instance,
21 body temperature may have nothing to do with propensity to cardiac event as shown by lack of
22 correlation between body temperature and historical occurrence of cardiac event. Further body

1 temperature may not statistically correlate with treatment methodology in the historical patient
2 data base. Thus, failure to have such data when presented with a cardiac patient with a particular
3 genetic sequence would not affect a proposed patient's treatment and the output would indicate
4 the missing data is not critical.

5 The feature of a directed course of treatment methodology for a certain patient profile of
6 fields of data can also be added, particularly at the early stages of the development of the
7 database.

8 The invention contemplates that a genotypic propensity may be seen in DNA sequences of
9 an ancestor and a patient-child of such ancestors. However, such propensity may be unlikely to
10 manifest if antioxidant capacity of the body is high and glutathione level is normal. At the same
11 time, a given environmental factor may aggravate propensity. By using this invention, a health
12 care provider can provide appropriate medical advice, and preventative therapy to maintain
13 antioxidant capacity and properly glutathione cycle function.

14 Even for incurable diseases, monitoring of redox imbalance and glutathione function can
15 ameliorate or arrest deleterious effects. The invention proposes to evaluate the propensity of a
16 patient with an apparently incurable disease to glutathione cycle malfunction, and evaluate
17 antioxidant capacity, and then administer therapy to restore normal glutathione levels and redox
18 potential, and enhance antioxidant capacity.

19 An example of the reference in the claims to "database capable of generating output from
20 the electronic results of a clinical chemistry analyzer and DNA sequencing machine is the
21 database described in the prior paragraphs. A combination of a DNA sequencing machine, a
22 clinical chemical analyzer such as one made by Roche Cobas Faras, both generating electronic

1 output, and a general purpose computer and the database discussed could generate preferred
2 treatment methods and expedite a health care providers' selection, and enable delegation of
3 proposed treatment to less skilled personnel.

4 The steps in the claims as a description of the practice of the invention and are
5 incorporated by reference. The claims set out the programming steps and modules needed. A
6 variety of database management languages can be used as well as any number of database
7 management packages known to those skilled in database management arts and analysis.

8 Electronic security measures (normally a password) are contemplated as accompanying
9 data sets or data bases referenced in this invention.

10 The invention is not meant to be limited to the disclosures, including best mode of
11 invention herein, and contemplates all equivalents to the invention and similar embodiments to
12 the invention for humans and animals and veterinary science. Other tests can determine
13 glutathione level, redox imbalance, and anti-oxidant capacity, and are contemplated in the
14 invention and claims.